Skip to content
Screener

Cytek Biosciences, Inc. CTKB Product — Total revenue, net

Other product segments

Service
$15.58M+9.8%

Similar metrics at other companies

Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Geron logo
GERNProduct revenue, net — Total revenues
$57.47M+17.3%
PTH
PTHSNet product revenues — Total Revenue
$10.67M
Evolus logo
EOLSProduct revenue, net — Total net revenues
$83.35M+21.3%
Corcept Therapeutics logo
CORTHypercortisolism Products — Product revenue, net
$208.58M+7.3%
Quanterix Corporation logo
QTRXProduct revenue — Total revenues
$23.48M+39.5%

Other financials

Income statement

See full
Revenue$48.1M+5.6%
Gross profit$28.3M+18.7%
Operating income-$11.4M-7.3%
Net income-$12.2M-118%
EPS (diluted)-$0.09-125%

Balance sheet

See full
Cash & equivalents$73.8M-2.2%
Total debt$17.0M-6.6%
Total equity$322.0M-14.7%
Total assets$446.9M-9.4%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+40.5%
Free cash flow-$849.0K+42.2%

Valuation

See full
Market cap$605.72M+25.6%
Enterprise value$548.91M+29.2%
P/S2.9×+0.5×

Profitability

See full
Gross margin53.2%-1.2pp
Operating margin-21.6%
Net margin-39%
FCF margin-5.8%-11.4pp

Returns & leverage

See full
Return on equity-23%
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053496
(In thousands, except share and per share data)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue, net:
Product$32,556$31,415$61,335$59,525
Service15,58414,18730,94027,534
Total revenue, net48,14045,60292,27587,059
Cost of sales:
Product12,88414,92128,80530,450
Service6,9166,81413,87612,585
Total cost of sales19,80021,73542,68143,035

Item 1. Consolidated Financial Statements (Unaudited)

FAQ

What is Cytek Biosciences, Inc.'s product — total revenue, net?
Cytek Biosciences, Inc. (CTKB) reported product — total revenue, net of $32.56M in Q2 2026.
How has Cytek Biosciences, Inc.'s product — total revenue, net changed year-over-year?
Cytek Biosciences, Inc.'s product — total revenue, net increased by 3.6% year-over-year, from $31.42M to $32.56M.
What is the long-term trend for Cytek Biosciences, Inc.'s product — total revenue, net?
Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s product — total revenue, net has grown at a 4.8% compound annual growth rate (CAGR), from $119.52M to $144.23M.
What does product — total revenue, net mean?
This metric represents the total net revenue generated specifically from the sale of physical instruments, reagents, and associated hardware products after accounting for returns, allowances, and discounts. It serves as a primary indicator of market demand for the company's core technology platforms and hardware-based solutions. Tracking this figure helps investors assess the commercial adoption and sales performance of the company's specialized equipment portfolio.

Ask your AI about Cytek Biosciences, Inc.'s product — total revenue, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude